ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

British Journal of Clinical Pharmacology

British Journal of Clinical Pharmacology

Volume 42 Issue 4, Pages 513 - 517

Published Online: 9 Oct 2008

Journal compilation © 2010 The British Pharmacological Society



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  Full Text: PDF (Size: 212K)  | Related Articles | Citation Tracking

Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine
W. C. SHYU & R. H. BARBHAIYA
  1 Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Lawrenceville, New Jersey, USA
Correspondence to: Dr Wen Chyi Shyu
KEYWORDS
butorphanol • transnasal • cimetidine • pharmacokinetics

ABSTRACT

The potential for a pharmacokinetic interaction between butorphanol nasal spray and cimetidine, under steady state conditions, was evaluated in 16 healthy male volunteers. Subjects received either a 1  mg butorphanol nasal spray every 6  h or a 300  mg cimetidine tablet every 6  h on days 1–4, the combination of two compounds every 6  h on days 5–8 and the original treatment as described in the first segment (days 1–4) on days 9–12. Serial blood and urine samples were collected on days 4, 8 and 12, and additional blood samples were taken immediately, prior to the morning dose on days 3, 7 and 11. Based on the analysis of the Cmin samples, the plasma concentrations of cimetidine and butorphanol achieved steady state by the third day of dosing. No statistically significant differences were found in the plasma concentrations of butorphanol or cimetidine (except for t½ and MRT) between any of the treatment phases. Butorphanol nasal spray and cimetidine can be co-administered without any adjustment of dosage for either drug.


DIGITAL OBJECT IDENTIFIER (DOI)
10.1046/j.1365-2125.1996.4592.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Sign Up Now
Sign Up Now